BioAtla, Inc.
BCAB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.01 | 0.02 | -0.01 |
| FCF Yield | -24.45% | 0.00% | -80.63% | -56.83% |
| EV / EBITDA | -2.43 | -0.59 | 0.67 | 1.17 |
| Quality | ||||
| ROIC | 1,527.02% | -164.52% | -77.13% | -41.95% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.63 | 0.76 | 1.06 | 1.13 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 2,223,880.09% | 2,223,880.09% | 2,223,880.09% |
| Free Cash Flow Growth | 0.00% | 100.00% | 2.95% | -227.03% |
| Safety | ||||
| Net Debt / EBITDA | 0.14 | 0.66 | 1.82 | 3.01 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -736.98 | -2,310.49 | -14.69 |